Although recent therapeutic advances, such as exon skipping (Echevarría et al, 2018; McDonald et al, 2021) or stop codon read-through (McDonald et al, 2017; Welch et al, 2007), have resulted in the production of partially functional dystrophin in specific subsets of DMD patients, no curative treatments for DMD are currently available in clinical practice (Duan et al, 2021; Markati et al, 2022). This evidence concerns the gene DMD and Duchenne muscular dystrophy.